Call for Grant Applications (CFG) CFG-Immunology-2023
AbbVie Independent Education (IE)

<table>
<thead>
<tr>
<th>Therapeutic Area/Disease State</th>
<th>Immunology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focus</td>
<td>Advancements in JAK Inhibitors</td>
</tr>
<tr>
<td>Issue Date:</td>
<td>Wednesday, June 28, 2023</td>
</tr>
<tr>
<td>Due Date/CFG Close Date:</td>
<td>Wednesday, August 16, 2023</td>
</tr>
</tbody>
</table>

**Background**

AbbVie is committed to supporting independent, high-quality evidence-based education with the most up-to-date information on current, new, and emerging therapies. This helps to expand knowledge, competence, and performance to improve quality of care for patients.

**Eligibility Criteria**

Grant applicants must be US-based, registered in AbbVie’s Grant Management System at grants.abbvie.com with no outstanding reconciliations and authorized to provide accredited CME/CE by an official accrediting agency (e.g. ACCME, AOA, AAFP, AMA, ADA CERP, ANCC, ACPE, etc.).

**Transparency**

The AbbVie grant review and approval process is in full accordance with the recommendations and the guidance of the Office of Inspector General (OIG), Pharmaceutical Research and Manufacturers of America (PhRMA), Advanced Medical Technology Association (AdvaMed), the Accreditation Council for Continuing Medical Education (ACCME), “National Physician Payment Transparency Program: OPEN PAYMENTS” commonly known as the “Sunshine Act,” and internal AbbVie Compliance policies.

AbbVie, at its sole discretion, has the right to disclose the details of funded independent medical education activities, including those that may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount.

**Terms and Conditions**

AbbVie reserves the right to approve or deny any or all grant applications received as a result of this Call for Grants (CFG) or to cancel, in part or in its entirety, this CFG. AbbVie is not responsible for any costs associated with this CFG submission.
Submission Directions

1. Please go to grants.abbvie.com and sign in. First-time users should click “Register.”

2. In the grant application:
   - STEP 1. Select “Submit New Request” to start the submission process.
   - STEP 2. Select the “Education Requests” button to continue the submission process.
   - STEP 3. Read the Request Submission Instructions and click “Proceed” to enter the request form.
   - STEP 4. Enter Request Information on the General Information Tab.
       - In the Activity Sub-Type field, select Independent Medical Education
       - In the Program Title field, start the title of the grant request as: CFG-Immunology-2023
   - STEP 5. Continue entering requested information as outlined in the grant application, including document uploads.

3. If you have questions or require assistance, please contact:

   AbbVie Independent Education Department at 877-228-7177 or via email at abbviegrants@abbvie.com.

IMPORTANT: Grant applications submitted in response to this Call for Grants after the due date will not be reviewed by the AbbVie Independent Education Department and will be automatically declined. In addition, grant applications must include the required information outlined in the Submission Directions. Failure to provide this information may result in the grant application being declined.

Decision Date and Notification

Once AbbVie has reached a decision about the grant application, a system generated email notification will be sent. If the request is approved, the Authorized Signer identified in the grant application must log into the AbbVie grant management system to review and approve the Letter of Agreement. The Letter of Agreement must be electronically signed by all parties prior to the activity start date. Please do not consider any request approved until an email notification is received from AbbVie stating that the grant request is approved.
Call for Grant Details

<table>
<thead>
<tr>
<th>Therapeutic Area/Disease State</th>
<th>Immunology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intended Learner Audience</td>
<td>Dermatologists, Rheumatologists, Gastroenterologists, and Allergists, as well as NPs, PAs, and other HCPs involved in the care of patients immune-mediated diseases. Programs that also include patient education may be considered.</td>
</tr>
<tr>
<td>Geographic Scope</td>
<td>United States</td>
</tr>
<tr>
<td>Submission Deadline</td>
<td>Wednesday, August 16, 2023</td>
</tr>
<tr>
<td>Notification Deadline</td>
<td>September 2023</td>
</tr>
<tr>
<td>Budget</td>
<td>$2,250,000</td>
</tr>
<tr>
<td>Anticipated Timing and Metrics</td>
<td>The ideal program launch timing will be Q4 2023. Interim and long-term sustained results should be reported. Please explain the rationale for the timing/duration of the program.</td>
</tr>
</tbody>
</table>

Statement of Need

Janus Kinase Inhibitors (JAKi) have been approved by the FDA for at least eight immune-mediated diseases, which have been studied extensively in both clinical trials and real-world settings. With the first JAKi approval, a post-marketing safety outcomes study was required based on imbalances in specific safety events observed in the Phase III program. Results were published that led to labeling changes for all JAKi that were indicated for at least one immune-mediated disease due to shared aspects of the mechanisms of action across the class. The safety profile of JAKi and in other immune-mediated diseases remains under assessment in both clinical trials and real-world routine and enhanced surveillance.

Considering the impact of the results of this single study on labelling for all different JAKi across immune-mediated diseases, and the extent of data obtained and ongoing from clinical trials and real-world evidence on JAKi benefits and risks, it is critical that healthcare providers (HCPs) utilizing these therapies are sufficiently educated on their safe and effective use in a manner that is consistent with FDA guidance and the latest available evidence.

There is a need to improve the overall care, assessment, and management of patients by implementing evidence-based recommendations for JAKi. Therefore, AbbVie is interested in reviewing proposals that include a strategic, comprehensive curriculum specifically designed to address clinical management considerations for JAKi across the indications for which these medications are approved. The goal is to ensure that appropriate patients will be carefully identified, treated, monitored, and managed to optimize patient outcomes and avoid potential adverse effects. Interventions that will lead to timely
and measurable improvements will be considered. All proposals should clearly describe the anticipated impact and improvements as a result of the education. Preference will be given to organizations who partner with major societies, academic medical centers of excellence, and/or known leaders in the immunology field.

References

1. Xeljanz Rheumatoid Arthritis (RA) FDA New Drug Application (NDA) Approval Letter. [https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203214Orig1s000ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203214Orig1s000ltr.pdf) (2012)